Trials / Completed
CompletedNCT06246461
The Therapeutic Effect of Different Doses of Capecitabine
Clinical Effect Analysis of Different Regimens of Capecitabine in the Treatment of Patients With Advanced Colon Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Jingjiang People's Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.Different administration regimens of capecitabine were given, and the treatment course was appropriately extended. The therapeutic effect and incidence of adverse reactions were observed.
Detailed description
To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group. Afterward, the response rate, quality of life, and adverse reactions of the three groups were collected for comparison.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine | The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2023-12-31
- Completion
- 2024-01-22
- First posted
- 2024-02-07
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06246461. Inclusion in this directory is not an endorsement.